News Hub | News Direct

KOL Webinar on Genetic Blindness Points to Promise of Kiora’s Pioneering Solution--Clinical Data in Q1

Kiora Pharmaceuticals

Retinitis pigmentosa (RP) is a cluster of genetic eye diseases that damage the retina, the light-sensitive layer of the eye. It typically affects people in their teens or 20s, although some variations initiate in children as young as 8. There is currently no cure for the disease, and it inevitably leads to total blindness. Stonegate Healthcare recently hosted an event focusing on the disease. “ Battling Blindness in Retinitis Pigmentosa: A Discussion of Disease & the Pipeline of Hope ” featured three speakers: Ben Shaberman of the Foundation Fighting Blindness, who provided a patient perspective, retinitis pigmentosa specialist Dr. Christine Kay, an inherited retinal disease specialist and Kiora Pharmaceuticals Inc.’s Chief Development Officer, Dr. Eric Daniels. A Simple But Elegant Solution RP has been a difficult disease for practitioners to tackle, and the U.S. Food and Drug Administration (FDA) has not approved any treatments to date specifically indicated for the condition. In many cases, the disease is diagnosed only after vision loss initiates. According to Dr. Kay, mutations in more than 65 genes can cause RP and whilst gene therapy approaches offer promise to addressing RP, the FDA would have to essentially approve 65 unique gene therapy treatments to address all the patients with RP. Timing of diagnosis of RP may also present challenges, and for many patients, it may be too late to qualify for gene therapy treatment. Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is a pharmaceutical company specializing in treating eye diseases with high unmet need. During the webinar, Dr. Daniels talked about the company’s novel treatment, KIO-301, which is in Phase 1b clinical trials. The study is expected to generate interim data before the end of this year, with top line results planned for the first quarter of 2023. Dr. Daniels describes KIO-301 as a “simple but elegant solution” to RP. KIO-301 does not focus on the photoreceptors in the eye, which die in patients with RP, but instead turns its attention to the retinal ganglion cell (RGC – the cells that comprise the optic nerve). RGCs are still viable and functional in RP patients — it’s the photoreceptors (rods and cones) that are failing. KIO-301 specifically enters the RGCs in the eye and makes these cells light sensitive. It is the hope that KIO-301 can restore significant visual functionality in patients with vision loss due to RP. The treatment does not interfere with native functional vision, which also makes it a potentially viable treatment for patients with less-advanced RP. RP specialist Dr. Kay is hopeful and excited about Kiora’s clinical trials. Patients Have Passion and Urgency For Treatment Mr. Shaberman provided the patient’s perspective, indicating that people with RP are passionate about finding a treatment to address their blindness and are willing to participate in early stage clinical research of novel therapies to find one. Dr. Daniels said Kiora has a long list of patients from around the world who would like to be part of the company’s clinical trials. What sets KIO-301 apart from other potential therapies, including gene therapy alternatives, is the ease of treatment. Dr. Kay said she is interested in KIO-301 because it is potentially safe, easy to administer and a reasonable approach to vision restoration. KIO-301 will be administered intravitreally, allowing most any ophthalmologists the capability to provide the treatment with no need for more invasive and expensive surgeries. The risk of infection is extremely low compared to other routes of administrations. “For patients with RP, even partial restoration of their vision can be life-changing”, Mr. Shaberman said. “RP is an emotionally burdensome disease for patients and their families. KIO-301 gives hope to patients who are eagerly awaiting a solution to their blindness.” To watch a recording of the event, click here. Click here for more information on Kiora Pharmaceuticals Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. Contact Details Thomas Redington tredington@redingtoninc.com Company Website https://kiorapharma.com/

October 31, 2022 08:01 AM Eastern Daylight Time

News Release

8 Best "Write My Essay For Me" Websites: Pay Someone To Do It For Cheap

Genuine Papers

It takes more than sheer grit to achieve success. After all, success is a function of a well-planned endeavour. You do not rush into it. You do not scurry into it. You do not stumble upon it. It does not happen to you by chance. Instead, it is a result of a well-thought-out plan and execution. And in this execution, there is a clear understanding of personal abilities, strengths, and weaknesses directing the approach of such a success plan. The ants know this. So, there is a clear-cut division of labour amidst them. And that is why they have thrived for so long despite the harsh climatic conditions they have had to live through. Thus, it only makes sense that for you to achieve such excellence as you so desire in your academic pursuits, you must engage the services of people who know their onions on the task. Essay writing is one of the things many students need help with. Some of them cannot do it. But is that a bad thing in and of itself? No. Why? Because many life contexts determine different life approaches. An immigrant undergraduate student who juggles three jobs would have little or no time to sit down before a computer and type long (or even short) essays. The same goes for a family man who, after a long day in school, still has to fend for his children at home. At the same time, some students do not have a strong command of the English language and can not write coherent essays. So, should these folks suffer in their academic pursuits because of their life situations? Definitely not. And this is why we are introducing you to the 8 best "write my essay" services with affordable prices. These websites are specifically for you if you need help accordingly. 99Papers - the best "write my essay for me" company overall. Studdit - professional paper writers from the USA. EssayPro - the cheapest website to write your essay. PaperHelp - top-rated company to pay someone for an essay. EssayFactory - popular "write my essay in the UK" service. SpeedyPaper - writers that can do your essay faster. EssayBox - affordable college paper writing provider. Ivory Research - admission & application essay service. In case you are wondering what our criteria for choosing these "write my essay" websites are, then you have a valid concern. We picked these sites based on their attention to detail, careful and prompt delivery, excellence in their written essays, customer service and support, customer satisfaction, and pricing. So you do not have to worry about “who would do your essay for you” anymore. We've got you covered! TOP 8 “Write My Essay For Me” Websites to Get Writing Help Online #1. 99Papers 99Papers is a TOP rated "write my essay" service with all you would ever need to get ahead in your academic pursuits. From high school to postgraduate studies, they attend to all kinds of essay needs that you might have. And not only that, but they also deliver excellently on all of them. Thus, not only are they capable, but they are also reliable in meeting your writing needs. They are the best essay writing website you can order from. This claim is not without proof. Many positive comments and feedbacks on how well they have delivered on client tasks are available on reliable review sites such as Trust Pilot and Sitejabber. Similarly, they have great feedback with customer-specific details on their website for your consumption. All these reviews and comments point to the premium quality work that 99Papers delivers. They are at the forefront of excellence according to the industry standard. Likewise, they lead many other sites with the affordability of their essays. You do not have to break the bank before you order from them. You would get an original essay written from scratch for just $9.95 per 275 words or 1 page. So, you can avoid plagiarism and any fake write-up detector software like Turnitin flagging your essay. It is a solidly written piece of work written by capable hands. To cap it all up, they are also prompt with their delivery of customer work. Further, talking of capable hands to handle your work, there are expert writers with sterling experience in both academic and writing spaces. So, they can take your order specification and turn it into an essay that ticks all the necessary boxes for you. Moreover, most of these writers are experts who have clinched postgraduate certifications themselves. Thus, they know how best to craft an essay for that academic difficulty and other lower grades. As a result, they can take on essays like academic essays, personal statements, dissertations, admission essays, and term papers. And each of these types can be attended to by a standard, top, or native writer, depending on your choosing. If you are considering discounts, some are available for you when you order from them. They tend to offer a 15% discount around the back-to-school period. They also offer a chance to win a free essay. And this can significantly affect the lump sum of the essay in general when taken advantage of. #2. Studdit Studdit is one of the recent additions to "write my essay" companies in the market. And despite their newness to the game, they have shown incredible feats as what they are capable of handling. With thousands of essays written for students worldwide, and good reviews by many who have patronized them, Studdit has shown itself to be a reliable site to order from. Moreover, as a sign of good faith, this site offers you money-back as well as plagiarism-free guarantees. Thus, they pose as a secure place to order your essays from. Further, the customer journey on their site is hassle-free. It involves less time for wandering and wondering. You can place an order with a clear description of terms and an easy process. All you have to do is check out a simple calculator and a form to fill out. And in case you need answers to some questions that might be bugging your mind as you want to place an order, they have anticipated and answered these questions under their FAQs section. Little wonder many review sites commend them for their outstanding customer service and support. They are keen on helping out their clients with the slightest inconvenience. And that shows how reliable they are to work with. It would be an absolute disaster if a site had great customer support but bad essay deliveries. That is one of the ways Studdit separates itself from the pack. This site is excellent across the board. With client inquiry and premium-quality work, they deliver remarkably on all fronts. They respect deadlines and stipulated delivery timeframes. They also create fresh and from-scratch content with 0% plagiarism queries. And all these are attributed to their sea of seasoned writers. These are professional writers from the USA. These writing experts give their all to meeting all of Studdit's clients' needs. They are academics themselves with Masters' and PhD degrees. Thus, they can help with pretty much anything a student needs, including homework. With as low as $13, you can order stellarly-curated content. However, with the specifications of your order, the price might increase or decrease. If you apply a discount code, it will lower the pricing for the essay. However, with factors such as academic difficulty level, the grade of the writer writing your essays, plagiarism reports, VIP service etc., the price of your order is likely to increase significantly. For discounts, Studdit likes to add to the overall experience of its customer by including 25% off on their first order. #3. EssayPro EssayPro is a pro essay writer because of the speed of their turn-ins. They have a reputation for sending in essays within a short period. Once you stipulate your deadline, they get your task to you at said time. And they do this for a wide range of essays that you can think of. These include term papers, dissertations, research papers, personal statements, admission essays, theses, etc. All these are essays written for high schoolers as well as for persons who are presently in tertiary institutions. And guess what? Persons in postgraduate studies are also not exempted from their league of clientele. You should know that EssayPro is a sucker for excellence. And that shows in the rigorous process they take their writers through they are finally admitted. These procedures are not to misuse them. Rather, they are duty-of-care processes that separate the wheat from the tares. Thus, only the best of the best writers, who are culture-fit for consistent delivery of quality work despite the huge workload, are retained. There is always the ID and Diploma verification stage for the writers they recruit. Then, they are asked to send in samples of their previous works. Further, test jobs are assigned to them before they are admitted into a full-time hire, howbeit probationary phase. In contrast, placing an order on the EssayPro site is an entirely different ballgame. It is simple and seamless as opposed to the recruitment scheme for most of their writers. You first fill out the order form. This usually includes details about the length of the essay, the topic, and the academic level of such an essay. At this stage, you can surely provide them with samples you have worked on before if you have. This is so the writer can tailor the essay to your writing style. Once you have finalized the order information, you can choose which writer to work on your task. You can check out their profile here as well as the field of specialization. You're also open to chatting with them to know the right fix for you. Having done all this and you have made a choice, you can then make a deposit and place the order. Their market pricing is also quite fair, and you can get an excellent essay for just $10.8. But like other sites, the delivery stipulations, whether high school or undergraduate level writing, would also determine the increase or decrease of the price slide bar. #4. PaperHelp PaperHelp is truly that “write my essay” site that you can pay to get your writing needs to be sorted for you. Why? There are a couple of reasons that have informed this claim. And a major of them is the quality of their essays. It's sterling. Most of their previous and current customers have testified of their special deliveries. The specifications are fully adhered to, as well as the time of submission. The students who order from them have grades ranging between B- and A. This tells you that they are good at what they do. Another feature of their services that stands them out is the referral program they run. This involves students and others sharing their services with people outside the platform. And once those referred people sign up and order, the one who refers gets a discount on the essay orders they place. This feature has been integral to the fast growth of PaperHelp in the essay-writing market. Further, you can order any writing needed on PaperHelp. What this means is that not only can you write with them, but you can also edit and proofread your already-written essays. You could also run calculation jobs by them. They have capable hands ready to turn your essay challenges into an amazing body of work that would earn you a high grade with your lecturers or supervisors. Interestingly, it does not matter the topic or deadline. What counts is the number of words and type of paper you need to be written. And you would be amazed at the original content curated for you by these expert writers. With PaperHelp, their essays begin at a pegged price of $12. This is a low price for many students, which is affordable for them to pay. And considering that there is an underlying guarantee of a possible high grade, such a price is too small to pay for such a top-grade essay. And things get more interesting when you realize they have a couple of discounts up their sleeves. For example, you enjoy a 15% discount on your first order. Then, when you refer people, you get 10% off too. #5. EssayFactory EssayFactory is that professional “write my essay for me” website. That requires little or no monitoring. As much as you have placed your order on their site, you can rest assured that you will get an excellent delivery on your job. This is especially if you are in the United Kingdom. They are a popular "write my essay in the UK" service. Of course, they service writing needs across the globe. However, contact them if you are a UK student and need an essay writing company. They are excellent, fast, and reliable. They write in good British English, just as you need. Further, they also offer editing services if you are not looking to order a custom essay from them. This would enable them to tweak your essay the way you want for high-grade submissions with your professor or teachers. And the process of doing this is so simple. It works the same way as the custom essay order procedure - fill out the form on their site. The academic level has been tweaked to reflect the UK school system. You can choose university level or A1/A2 for A-level courses. EssayFactory pricing starts from £11.50. However, where it ends depends on what you pick while you place the order. That is the delivery period, the essay's academic difficulty, and many extras that you might want in the delivery, such as the plagiarism report. But here is something to get you excited, they have many discount options you can leverage as you order essays on their website. There is a 25% off discount code. You can also get your 5th essay for free if you paid for it. You could also get your 7th assignment for free if you booked 6 assignments within 7 days. There are also 10% and 15% discount deals that you can take advantage of when you place an order on EssayFactory’s website. #6. SpeedyPaper SpeedyPaper is known for what its name represents – a speedy submission of ordered papers. And the most interesting part is that it does not tamper with the work's quality. The prompt delivery does not negatively impact how well-written the essay is. SpeedyPaper would still create original content for you suited to your order specifications. They present you with a pool of choices to pick from as regards the services you want them to render to you. Their work is not limited to writing alone. They can also help you to edit, rewrite, problem-solve, mark or even just proofread your essays and homework. The company can pull this off through its remarkable expert team, which has repeatedly proven that it can handle whatever the customers bring. Thus, the company pumps a lot of effort into picking the best writers to work for them. And they do this via a thorough process of recruitment. This is to preserve the consistent reach of excellent essays to clients who approach them with “write my essay” requests. They also do this to hire folks who can engage speedy processing of client orders as well as prompt delivery. Further, ordering from SpeedyPaper is not a strenuous job. Filling out a form is the major thing to do. And that included inputting the title of the paper, length of the essay, delivery time, style of writing, etc. You can provide them with a sample of work you have done before to maintain a consistent approach to all of your essays. It would help them get a better understanding of your writing style. After this, you can then make payments and finalize the order. Pricing is also one of the things that endear many clients to SpeedyPaper. With just $11, you are assured of prompt delivery and excellent work. In addition, there are a lot of discounts on their service. For your first-time order, you get 11% off your payment. In a referral program, you and your referred friend get 10% off your orders when they join the platform. There are also Labor Day, Youth Day, and Independence Day offers with 15%, 12%, and 15% off, respectively. #7. EssayBox EssayBox is popular among college students. This is confirmed by the numerous positive reviews of their customers. It is easily seen in how much EssayBox has shown itself as a reliable "do my essay" platform for them, especially regarding the speed of delivery. When you order from them, you can be certain of two things. One is that the essay written will not be less than average quality. And two, you will get your essay at the stipulated time you noted that you want it. These two services have won the hearts of many college students in the country. They have presented you with a clear way to order from them. Like many other essay writing websites, you can easily find your way across their company site. This is to show you their commitment to great customer support and service. On their homepage, you get welcomed by the price calculator above, in which you will find the form to fill in the details of your order. As you input the information about your task, the price will be progressively curated to know the amount you would be paying at checkout. And this is commonly affected by the number of pages in your essay, the delivery timeframe, academic level, and what type of essay it is. Some extra services also attract more fees, such as priority support, type of writer - native speaker or top writer, plagiarism report, copy of sources, a 1-page summary, and other extras. Just like the others, their pricing per page is not unbearable. This means that with just $12, a high schooler can get an essay that makes them a candidate of distinction in such a course or subject. They also offer a 15% back-to-school bonus, which can be helpful when ordering from them in subsequent times. #8. Ivory Research Ivory Research has been active in the “write my college paper” space for almost two decades. That shows they have established themselves as an authority in the market. They have the experience to meet writing needs with their ever-ready team of expert writers. They have been helping students to reach their academic goals in school, both undergraduate and postgraduate, since 2005. They help you take care of your assignment, so you can focus on other things, such as upping your grades. They have helped thousands of students with short essays, dissertations, theses, term papers, research papers, and exam preparations. In the UK, they have a stronghold in the market as they are one of the most reliable to work with. Students reach out to them, and they have more than enough hands to tend to all writing needs that comes their way. Furthermore, their customer support is one of the best in the industry. They have agents who are ready 24/7 to answer questions, resolve queries, and respond to inquiries from customers and clients worldwide. These consistent interactions and communication put your mind at rest that the best hands in the market are handling your work. Thus, delivery of original content, as well as prompt delivery, is thereby ascertained. The pricing for Ivory Research is one of the most dynamic in the market. And the reasons of based on their ordering system. Thus, the price can vary. And it usually depends on the grade you want to achieve with the essay. For instance, you could get a 1000-word essay for $132, and it's targeted towards a 2:1 grade. However, there are some discounts you could leverage on their website, which could lower the price. Questions & Answers What is an essay? An essay is a form of writing that talks about a specified topic. It could give an overview of the topic or niche-down and discuss sub-topics in such fields. Essays could also relate to taking a side on a given topic. This is usually referred to as an argumentative essay. And here, you approach it from a "for" or "against" perspective. That is, you could argue for such a topic or offer points against it. The other forms of essays include discursive, persuasive, narrative, and descriptive essays. Moreover, one thing is consistent with all these types of essays. And that is a clear outline of thoughts, whether prosaically or argumentatively. Further, most essays are academic. And they are usually regarded as a yardstick for academic performance. Thus, at the middle or end of a teaching term or semester, teachers usually request an essay to test the student's knowledge of the topic taught during that time. And such essays are used as a grading tool for the student's grasp of the topics discussed or taught. Is “do my essay” websites legit to use? “Do my essay” websites are very much legit. They are a safe landing for you when you want to clinch that high grade in your academic pursuits. They are legit because you would not be breaking any law by ordering your essays from them. As a matter of fact, these websites are companies with legally-backed registrations that are government-compliant. Thus, you are safe when you order from them. You do not need to worry about committing any criminal offence when you seek essay assistance from them. Well, simply because you would not be committing any. Also, these websites are legit because they do not offer you plagiarized content as an essay. And alongside, your information is safe with them. So if you are worried about your details leaking on the internet, you should put your mind to rest. This is because they all have a strict anonymity policy where they are discreet with the information of all their customers and clients who place orders on their websites. Is it safe to order college essays online? It is 100% safe to order college essays online. In case you are wondering why, you have to realize that these services are available to assist with your academics. And tons of reviews online would point you to the fact that they are reliable means of getting your essays written. The major reason most customers leave these positive reviews is the level of excellence that accompanies their write-ups. Expert writers on each platform deliver their essays with premium quality—no plagiarism. Rather, you would have access to plagiarism reports upon request. The only moment it becomes unsafe to order college essays online is when you order from unreliable websites. Unfortunately, many sites are posing as original while they are simply fraudulent platforms in disguise looking to scam you. This is why we have a curated list of the best and most trustworthy websites to get your essays written. All you have to do is consider any of them that fits your bill and choose them for your essays. Do professors know if you bought an essay? No. In case you have been wondering, your questions have been answered today. Your professors do not know if you bought an essay. Rather, they are impressed at the excellence of the essay you have submitted. You see, irrespective of your academic level as a high schooler, undergraduate, or even postgraduate, your professors cannot detect that you buy an essay online. Your professor (or any essay detector software like Turnitin, for that matter) cannot detect that you bought an essay online because the essays are original content. The essays written by the "write my essay" websites are written from scratch, and they are with 0% plagiarism. How many students pay for their essays? Don't be surprised that most of the students you know have paid for their essays at one time or the other. It is not a crime to do so. On the contrary, they are absolutely justified to have done so if they ever did. And the reason is that they needed assistance and requested experts' help to write their essays. As a result, most of these students end up topping their classes. And that's because their essays were written by people who have been in their shoes. These specialist writers are academics, and most have bagged postgraduate certifications. Who can write my essay for me? There are many essay writing services online for you to take advantage of. Our 8 best "write my essay for me" websites list to pay someone are reliable online platforms that can write your essays for you. These companies hire the best hands every time to tend to the varying writing needs of their customers and clients all across the globe. If you need someone skilled, experienced, and who respects prompt deliveries of essays, then you should reach out to any of the services highlighted above. They are well and able to write your essays to your satisfaction. Where can I pay someone to write my essay? If you want to pay someone to write an essay for you, you can check out 99Papers. They are the best essay writing platform overall. Why? Because they offer a relatively cheap price per page to get started on your essay. Not only that, but they also have a solid team of expert writers who can take on any writing need you might have. These take care of term papers, admission papers, research papers, high school essays, personal statements, etc. They also have 24/7 customer support that listens and attends to the inquiries of all persons with challenges on their website. Thus, you can track the progress of your essay as it is being written. Therefore, 99paper is a great choice to consider when looking or where to pay someone to write your essay. Who can do my essay faster? Do you need your essay delivered fast? Try SpeedyPaper. You do not have to worry so much about them delivering your job when you need it. They are quick and prompt with their delivery. As you specify the deadline by which you need the job, they swing to action to write your paper with the best resources available to them. And guess what? The speed of their submission does not affect their resolve to give you a great customer experience in the quality of the work itself. Thus, you get to tick all the boxes with excellent delivery and great submission. Also, the pricing for the essays is not so high that they are not affordable to you. Most speedy services would have increased their price for fast delivery. SpeedyPaper approaches this with a rather considerate pricing system. What is the cheapest "write my essay" website? EssayPro is your best bet here. When you are in a fix to choose the cheapest “write my essay” website, know that EssayPro is that one-stop shop that provides you with good delivery, great essay, and plagiarism-free content without charging you so high that you have to break the bank. You can get an excellent essay for just $10.8. And this package also includes many offers like delivery of your essay as and when due. Further, several discount options could benefit you and reduce the cumulative price of your essay order. Some of these codes are available online for your use. Write my essay in the UK... What is the best service? Are you a UK student looking for the best essay writing service? We think you've come to the right place. With loads of reviews online to back this up, EssayFactory has distinguished itself in the UK market as the best "write my essay" plug for students with writing needs. So, contact them today if you want to score a high grade on your essay. Also, know that they address both writing and editing needs. So, they can help you to fine-tune your written essays to a distinction level. Further, they are open to assisting you with various services such as term papers, research papers, admission essays, dissertations, theses, etc. So all you need to do is reach out to them, and they will give you the best writing experience in the UK. What are the best working “write my essay” discounts and promo codes? It does not only count that you order on these websites. It also matters that you take advantage of all possible benefits that they might have to offer. Some of these websites have discount codes available that you can enter to lower the cumulative price of your order. However, if you are looking for the best working “write my essay” discount codes, then the following are available for you to use. If you decide to go for 99Papers, you can get a 5% discount with the code – “ UVFUNPKM ”. If you are using EssayBox, take advantage of 5% off with “ 42UQLDIE ". Do you plan to use EssayFactory? Then a 5% discount code is “ DORF3RMY ”. And now we can sum up... As a student that needs help, do not drown in the ocean of essays. You can get help. We know that it can be a bit demanding. A bit? Scratch that. It can be very overwhelming such that you get lost in a maze of wanting to get high grades and finding enough time, the right resources, and the required experience to write essays that would deliver the grades you so desire. And do you know the most beautiful thing about this? There is a way out. You can always ask for help. And that from experts who are ready to assist you with any of your writing needs. So, what are you waiting for? Open up your arms and order essays from professionals looking to craft an original essay for you. Their write-ups are plagiarism-free as well as void of any forms of grammatical errors. In fact, if you ask for it, they will give you a plagiarism report that affirms their claim on your essay. They also deliver your essay as and when due. And their websites are available for you to peruse. Write your essays with them today! Contact Details Robert Claus writemypaper@best-essay-services.com

October 29, 2022 12:37 AM Eastern Daylight Time

Can Big Data Make Patient Care More Personalized And Effective?

Know Labs, Inc.

It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets be applied within healthcare to help drive innovation and improve patient care? The medical diagnostic technology company Know Labs Inc. (OTCMKTS: KNWN) is one such company that plans to leverage patient data to improve how patients and physicians manage specific conditions and enhance modern practice. Data Science — Bringing Advances To Patient Care And Diagnosis Data by itself may not necessarily always be useful knowledge. But it’s being successfully integrated with domain knowledge to analyze big data, a practice better known as data science. What makes data science in the healthcare industry important is that current and traditional study design and analytical approaches can sometimes be inadequate when taking on an unprecedented volume of large and unstructured datasets. Data science looks for new and increased knowledge, enhancing a more precise patient-focused medicine approach leading to more cost-effective drug discovery and advances in patient outcomes, care, and delivery of care. In general, it can be applied across a myriad of health care use cases. Large pharmaceutical companies and research and development hubs like Merck & Co. Inc. (NYSE: MRK) and the Mayo Clinic are increasingly analyzing vast amounts of data to gain new insights. Some of the world’s technology giants are also joining traditional medical research hubs to purchase new artificial intelligence (AI) startups. Those tech companies include NVIDIA Corp. (NASDAQ: NVDA) and Alphabet Inc. ’s (NASDAQ: GOOGL) Google and DeepMind Health AI service, which is being implemented in the United Kingdom National Health Service’s practice of alerting healthcare workers in the event hospital patients become at risk for acute kidney injuries. This advancement in data science is also reportedly helping researchers better understand how a disease behaves on a much more rapid timeline, including how scientists have studied SARS-CoV-2 and COVID-19 viruses. Scientists now know much more about how the virus infects the body, its treatment and the risk of severe disease because of the data sharing that has taken place among global researchers. At another company, Johnson & Johnson (NYSE: JNJ), these rigorous methods may eventually help improve treatments for — and potentially intercept the onset of — many deadly diseases. The company is leveraging data science in its clinical trials for lung cancer and pulmonary arterial hypertension and diversifying its clinical trials. Know Labs Inc. is working specifically to advance the practice of blood glucose monitoring in diabetes patients by offering what it believes will be the first genuinely non-invasive U.S. Food and Drug Administration (FDA)-cleared device. Tens of millions of people in the US suffering from diabetes may soon see assistance with some of the challenges, pain and expenses associated with managing their condition. The Seattle-based company looks to provide medical-grade and cost-effective solutions for people with type 1 and type 2 diabetes, people with prediabetes and people without diabetes who are interested in monitoring their blood glucose levels. Upon achieving FDA clearance, the company says it plans to expand its patented technology platform, Bio-RFID, to other medical diagnostic applications, including detecting and measuring levels of ketones, alcohol, metabolized drugs or other substances in the body. Know Labs Uses Its AI Platform For Diabetes Patients Know Labs recently launched a new subsidiary, AI Mind Inc. (AIM), which is focused on identifying opportunities to use the company's AI, machine learning and proprietary algorithms, which control its Bio-RFID platform, enabling it to identify and measure blood glucose levels accurately and noninvasively. Because of the development of the company’s AI engine, Know Labs states that it can process vast amounts of data to identify properties or trends while also recognizing patterns — this is viewed as an essential element of the company’s noninvasive blood glucose monitoring devices. The Company published results from internal tests demonstrating that Bio-RFID achieved a glucose measurement accuracy between 93% and 94% ( MARD 6.7% ) when compared to fingerstick glucose measurements. Know Labs’ product development team believes that continued development of its AI Engine and algorithms has the potential to further improve Bio-RFID’s accuracy. According to a study by Fortune Business Insights, the global healthcare analytics market size is predicted to reach $80.21 billion by 2026. The report highlights healthcare big data as a vital factor in boosting the healthcare analytics market revenue during the forecast period. Contributions by companies like Know Labs could build a more integrated, affordable and hassle-free healthcare future, with enormous benefits for patient care and health management. For more information on Know Labs Inc., visit knowlabs.co. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Know Labs info@visualant.net Company Website http://www.knowlabs.co

October 28, 2022 08:00 AM Eastern Daylight Time

A Promising New Treatment For Dementia Could Help Patients Manage Side Effects Better

Kurve Therapeutics

Mahatma Gandhi said that “the true measure of any society can be found in how it treats its most vulnerable members.” As life expectancies continue to increase, there is an ever-greater need to tackle health problems that afflict the elderly, the fastest-growing segment of the vulnerable. Neurological disorders — often resulting from debilitation of the central nervous system (CNS) — affect 1 in 6 people globally. In the U.S., 6.5 million people are affected by Alzheimer’s, a common CNS disease. This number will only increase as the group most at risk from Alzheimer’s disease — people older than 65 — continues to grow. Kurve Therapeutics Inc. is looking to bring real treatments for those suffering from Alzheimer’s and other neurological conditions. It is now open to investment from retail investors through a Regulation A+ offering. Investing In The Future Of Brain-Healthy Treatment Several diseases can affect the brain as the body ages. Dementia is a common disease where brain deterioration causes memory loss and cognitive impairment. While slight memory impairment is a common consequence of aging, contrary to popular belief, dementia itself is not a natural part of aging. Alzheimer’s is the most common form of dementia, though neurodegeneration accompanies several central nervous system diseases, including Parkinson’s (affecting 8.5 million globally) and multiple sclerosis (2.5 million globally). The medical landscape is struggling to find solutions that effectively treat Alzheimer’s. Despite expensive investments in drug trials and development, most drugs on the market are not disease-modifying treatments (DMT). Instead of modifying the disease, they provide short-term symptomatic treatment. Inability to bypass the blood-to-brain barrier (BBB) and the invasive, deleterious side effects common to most drugs on the market make such treatments unappealing. Furthermore, the development of disease-modifying treatments has been prevented by the inability to bypass the blood-to-brain barrier (BBB). Kurve is looking to change the scene. It claims that its ViaNase Intelligent Delivery treatment — featured by peer-reviewed journals like John Hopkins Medicine and Medscape — can bring actual DMT solutions with minimal side effects to those afflicted with Alzheimer’s and other neurodegenerative diseases. The journals report statistically-significant improvements (compared with placebo) in Alzheimer’s (five clinical trials), Parkinson’s (one clinical trial) and other CNS disorders. ViaNase involves a novel nose-to-brain delivery that allows the medication to bypass the BBB via olfactory nerves. Using Kurve’s patented controlled-particle dispersion (CPD) technology allows the ViaNase treatment to be administered with greater dosage control. This manages side effects, as the medicine is treating only the targeted area and allows greater precision for medication dosage. Through its innovative nasal treatment, Kurve is cutting a new path into the flourishing nasal-delivery technology market. Retail investors can now buy shares of Kurve. Its Regulation A+ offering is for $50 million, at $5.80 a share with a minimum investment of $580. Its primary target markets for the drug are Alzheimer’s, Parkinson’s and diabetic cognitive decline. However, it hopes to expand via its secondary market to treat a wide variety of CNS diseases. To learn more about Kurve Therapeutics, click here. Kurve Therapeutics ' drug delivery technology is designed to target the most difficult part of the treatment process — getting medication through the blood-brain barrier and into the brain.Kurve Therapeutics has 18 peer-reviewed publications of clinical trials using their breakthrough technology, with further publications pending. The company has recent and ongoing collaborations with leading research centers including Harvard, Johns Hopkins, and the Karolinska Institute.Through the development of their patented Controlled Particle Dispersion® technology, Kurve Therapeutics aims to reshape the landscape of cognitive aging, neurodegenerative diseases, and related disorders. Its next-generation technology has been shown to deliver up to 30x more disease-modifying medication directly to the brain than infusions in several Phase II studies. This allows for significant dose flexibility away from toxic doses for a safer, more efficacious therapy. While traditional treatment options continually prove ineffective at stopping neurodegenerative disease progression and often lead to toxicity or continued decline, Kurve is developing a new disease-modifying approach. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details Kurve Therapeutics info@kurvetx.com Company Website https://kurvetx.com/

October 28, 2022 08:00 AM Eastern Daylight Time

Keeping Cognitive Health Top of Mind

YourUpdateTV

Cognitive health is an essential component of our overall well-being as we age.1 Recently, Dr. Jeffery Blumberg participated in a nationwide satellite media tour to discuss new study results released on the large-scale, clinical trial COSMOS-Mind, which suggests that those who took Centrum Silver demonstrated improvement in cognitive function in comparison to the placebo. A video accompanying this announcement is available at: Finding a way to support cognitive function in older adults is an important public health issue, as roughly two out of every three Americans experience some level of cognitive impairment around the age of 70.2 Centrum, a leader in multivitamins for nearly 50 years, has a long history of supporting research to advance the science on benefits of vitamin/mineral supplementation. It is the most clinically studied multivitamin brand in the world. In continuing with this strong heritage, Centrum Silver product, placebo, and packaging was provided in support of the Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) trial. Centrum Silver was specifically selected for the COSMOS-Mind trial which investigated the effects of multivitamin and cocoa flavonoid consumption on cognitive functioning in 2,262 women and men, 65 years and older, over the course of three years. The COSMOS-Mind team tested each participant’s cognitive function via baseline and annual cognitive assessments.3 The results of the COSMO-Mind Study show that an intervention as simple as taking Centrum Silver could help support cognitive function, memory, and executive function in older adults.4* Participants who took Centrum Silver showed significant improvement in their episodic memory – the memory that is tied to specific events or experiences, as well as their executive function as compared to placebo.5 A detailed report on the COSMOS-Mind Study published in Alzheimer & Dementia Journal can be found here. For more information on Centrum and Centrum Silver, please visit Centrum.com. * This product has not been evaluated by the Food and Drug Administration. This Product is not intended to diagnose, treat, cure, or prevent any disease. About Dr. Jeffery Blumberg Health & Nutrition expert Dr. Jeffrey Blumberg is an active professor emeritus in Friedman School of Nutrition Science and Policy at Tufts University, whose experience leans into the promotion of cognitive health. Dr. Blumberg is available to discuss the importance of overall health and nutrition with an emphasis on the recent COSMOS-Mind findings and the potential benefits of taking multivitamins like Centrum Silver. About Centrum Centrum has spent decades listening to the human body and learning about what it needs to thrive. The brand offers nutritional products that work in harmony with your body and help you respond to its unique needs. Innovation and research remain to be the building blocks of the brand’s foundation. For more information about Centrum, please visit www.centrum.com. About Haleon US Haleon is a leading global consumer health company with a portfolio of brands trusted daily by millions of people. In the United States, the organization employs more than 4,700 people who are united by Haleon’s powerful purpose to deliver better everyday health with humanity. Haleon’s products span five categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Wellness. Built on scientific expertise, innovation, and deep human understanding, Haleon’s brands include Abreva, Advil, Benefiber, Centrum, ChapStick®, Emergen-C, Excedrin, Flonase, Gas-X, Natean, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, Voltaren, and more. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com. 1 Cognitive impairment in the U.S.: Lifetime risk, age at onset, and years impaired. PMC (nih.gov). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153285/. Accessed 3/24/22. 1 Cocoa Supplement and Multivitamin Outcomes Study for the Mind. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT03035201. Accessed 3/24/22. 1 Executive Functions | Memory and Aging Center. https://memory.ucsf.edu/symptoms/executive-functions. Accessed 3/24/22. 1 Executive Functions | Memory and Aging Center. https://memory.ucsf.edu/symptoms/executive-functions. Accessed 3/24/22. 1 Perceptions of Cognitive Health Factsheet. CDC. https://www.cdc.gov/aging/pdf/perceptions_of_cog_hlth_factsheet.pdf. Accessed 3/24/22. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 27, 2022 11:58 AM Eastern Daylight Time

Video

A New BioTech Research Race Is Focused On Improving Life For MS Patients

Pasithea Therapeutics Corp.

Learn More about Pasithea Therapeutics by gaining access to the latest research report When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is perhaps the case with multiple sclerosis (MS), an immune-mediated disease affecting the central nervous system, which according to the National Institutes of Health, continues to grow. The estimated number of people with MS worldwide increased from ~2.1 million in 2013 to 2.8 million in 2020, with the global prevalence at almost 36 per 100,000 people. The increased number of cases has subsequently increased the demand for effective diagnosis and treatment of multiple sclerosis. A recent Fortune Business Insights report said the global multiple sclerosis drugs market size was valued at $23.68 billion in 2021 and is projected to grow to $33.17 billion by 2029. Rising MS Numbers Spur Increased Research As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment. The rising MS numbers are believed to be the primary catalyst in market expansion. Active biotech companies in the MS market today include Pasithea Therapeutics Corp. (NASDAQ: KTTA ), BioNTech SE (NASDAQ: BNTX ) and SIGA Technologies Inc. (NASDAQ: SIGA ) and Moderna Inc. (NASDAQ: MRNA), among others. Some are finding new research showing that an mRNA vaccine might also work in multiple sclerosis (MS). BioNTech and scientists at the Johannes Gutenberg University of Mainz hypothesized that an mRNA vaccine could work in a targeted fashion to help the immune system tolerate specific MS-related proteins without compromising normal immune function. The BioNTech team developed an mRNA candidate wrapping the genetic information coding for MS-causing self-antigens in fatty substances. A similar lipid nanoparticle is used in Comirnaty to protect the COVID-19 mRNA material until it reaches target cells, where it produces the antigen protein. The results were published in the journal Science. Pasithea Reports Progress In Pursuit Of MS Vaccine Development Pasithea, a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders, recently announced positive results from a preliminary preclinical proof-of-concept study of PAS002, its tolerizing vaccine program in MS. The Pasithea vaccine promotes immune tolerance to a specific myelin protein, reducing the severity of relapses and helping the test animals gain weight, indicating a better overall health status. “Although early-stage data, we’re thrilled with the results of this study and the strong preclinical efficacy data of our tolerizing approach,” Pasithea CEO Dr. Tiago Reis Marques said. While regular vaccines usually are designed to train the body to develop an immune response against a particular pathogen, tolerizing vaccines essentially do the opposite, acting as a “reverse vaccine.” Those vaccines train the immune system to tolerate a molecule, suppressing an unwanted immune response against it. Pasithea hopes that helping the immune system accept GlialCAM, PAS002 will prevent the attacks that cause myelin loss in the brain and spinal cord, thereby reducing disease severity and MS relapses. Another recent article in Science showed published research that scientists have discovered about the risk of an individual contracting MS. The study showed that MS increases 32-fold after a person is infected with the Epstein-Barr virus. However, the risk of developing the condition does not increase when other viruses infect the patient. The scientists also tested MS biomarkers showing neurodegeneration. There are currently 15 vaccines actively under development for the Epstein-Barr virus, most of which are in discovery or preclinical stages. The Modified vaccinia Ankara (MVA) vaccine under development by the Chinese University of Hong Kong is in Phase II. It uses the same technology as AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) on their COVID-19 vaccines. The most prominent company involved, Moderna, has started testing the vaccine mRNA-1189, which uses mRNA technology, in Phase I studies. If successful, the vaccine could be one of the first on the market for the Epstein-Barr virus. Though the Moderna vaccine does not indicate MS, it could eventually help with disease prevention. For more information on Pasithea Technologies, visit pasithea.com. Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://www.pasithea.com/

October 27, 2022 09:50 AM Eastern Daylight Time

This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

NanoViricides, Inc.

Learn more about NanoViricides, Inc. by gaining access to the latest research report New York City is investigating the cause of death for two people who died after contracting monkeypox. Though both of the deceased had higher fatality risk because of underlying conditions, concerns about the virus and its transmissibility have been growing. The current number of monkeypox cases in the city stands at 3,695. Overall, there are just over 28,000 cases of monkeypox across America. Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative. NanoViricides is a biotech company seeking treatments in the antiviral and nanomedicine space, developing a variety of drugs for diseases like COVID-19, shingles, HIV, swine flu and others. It is now hopeful as it begins developing a treatment to tackle monkeypox. Working Hard To Find A Cure NanoViricides isn’t monkeying around as it begins developing a drug for the disease. It believes itself to be well positioned in the biotech field to find a treatment. It is one of the few biopharma companies to have its own current good manufacturing practice (cGMP)-compliant manufacturing facility, meaning it follows the stringent Food and Drug Administration (FDA) regulations in all its novel drug development work. Plus, NanoViricides has a large library of broad-spectrum antiviral nanoviricides from which it can draw to test on pox viruses. It has the resources necessary to expedite the process of finding a proper treatment. It hopes to develop a systemic treatment — one that is both oral and injectable — and may also work on a skin cream to treat the rash associated with monkeypox. The quicker these treatments can be rolled out, the sooner they can help those infected with the disease. New York City’s health department responded to the two recent deaths with a statement: “We are deeply saddened by the two reported deaths and our hearts go out to the individuals' loved ones and community. Every effort will be made to prevent additional suffering from this virus through continued community engagement, information-sharing and vaccination.” NanoViricides believes it will be able to develop a drug in response to monkeypox in relatively quick order. Meanwhile, the company’s priority remains the development of its drug candidate NV-CoV-2, for treating COVID-19. To learn more about NanoViricides, visit its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

October 27, 2022 09:25 AM Eastern Daylight Time

Elsevier and the American College of Medical Genetics and Genomics Announce the Forthcoming Launch of Genetics in Medicine Open

Elsevier

The American College of Medical Genetics and Genomics (ACMG), the only nationally recognized US medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and Elsevier, a global leader in research publishing and information analytics, are delighted to announce the January 2023 launch of a new gold open access, online only journal: Genetics in Medicine Open ( GIM Open ), an Official Journal of the ACMG. GIM Open will complement ACMG’s flagship journal Genetics in Medicine ( GIM ), also published by Elsevier, and is designed to meet the evolving needs of the global medical genetics and genomics community and expand its open access publishing options. Published under Creative Commons license, all GIM Open articles will be immediately, permanently, and openly available online for readers to view, download, share, and reuse. This will enable authors to more easily comply with funder and institutional mandates, even as requirements continue to evolve. ACMG’s decision to expand the breadth of its openly available content directly supports its mission to improve personal and public health through the clinical and laboratory practice of medical genetics; advocacy, education, and clinical research programs; and the safe and effective integration of genetics and genomics into all of medicine and healthcare. “I am excited about our new gold open access journal that will be available to anyone, anytime, anywhere in the world independent of financial resources or library access. GIM Open will be an international journal with a focus on medical genetics and genomic medicine including all aspects of therapy,” noted ACMG retiring Chief Executive Officer Maximilian Muenke, MD, FACMG, who led the development of the new journal. “It will be a trail blazer for diversity, equity, and inclusion from a double anonymous review process of manuscripts, to the Editor-in-Chief and an editorial board that truly reflects our society in the United States and around the world. We are fortunate to work with our colleagues Robert D. Steiner, MD, FAAP, FACMG, and Jan Higgins, PhD, ELS, from GIM and our publisher Elsevier on the start of this new venture. As a medical geneticist who thinks that genomic medicine is the present and future of medicine, GIM Open will educate healthcare professionals to contribute to optimal patient care everywhere.” GIM Open’s eminent international editorial board will be led by Editor-in-Chief Bo Yuan, PhD, FACMG, Baylor College of Medicine, an internationally recognized expert in the field. “I am tremendously honored and excited to serve as the founding editor of this new journal that will actively support open science for the medical, scientific and research professionals in a broad range of specialties who comprise our ACMG community,” said Dr. Yuan. “Collectively, members of the editorial board and I are dedicated to the rapid dissemination of high quality, authoritative and cutting-edge medical genetic knowledge both within and beyond the genetics community with the ultimate goal of improving patient outcomes.” Louise Curtis, Senior Vice President, Life Sciences and Social Sciences, Elsevier, commented, “We are extremely pleased to expand our publishing portfolio with ACMG, building on our collaborative partnership with this prestigious society that began in 2022 with publication of GIM. Launching GIM Open strongly aligns with our mission to help researchers and healthcare professionals advance science and improve health outcomes for the benefit of society, and we share the commitment to inclusion and diversity at the heart of this exciting new venture.” GIM Open manuscript processing will include rigorous double anonymous peer review, a rapid submission to publication decision turnaround time, and an expedited publication timeline. Detailed instructions for authors and information regarding open access and publishing fees can be found here. Manuscript submission will open as of October 25, 2022. Papers submitted to GIM may be considered for publication in GIM Open if deemed more appropriate for that journal. It is Elsevier’s intention to submit GIM Open for inclusion in the major abstracting and indexing services at the earliest opportunity. As one of the fastest-growing open access publishers in the world, nearly all of Elsevier's 2,700 journals enable open access publishing, including 600 fully open access journals. In 2021, Elsevier published 119,000 gold or pay-to-publish open access articles, an increase of more than 46% over 2020, making Elsevier one of the largest open access publishers in the world. Notes for editors About Genetics in Medicine Open ( GIM Open ) Genetics in Medicine Open ( GIM Open ) is an open access journal with a broad focus on medical genetics and genomic medicine including all aspects of therapy. It will have a strong emphasis on diversity, equity, and inclusion and will have a double anonymous review process for submitted manuscripts. Positioned as an official journal of the American College of Medical Genetics and Genomics (ACMG) and the companion journal of Genetics in Medicine, GIM Open aims to be an international journal publishing research studies that advance the knowledge, understanding, and practice of medical genetics and genomic medicine for all continents. GIM Open welcomes submissions of Original Research, Reviews, Commentaries and Brief Reports in the areas of clinical genetics, cytogenetics, molecular genetics, biochemical genetics, reproductive medicine, cancer genetics, pharmacogenomics, clinical trials, population genetics, public health, genome-wide association studies, polygenic risk, bioinformatics, methodologies, clinical implementation, ELSI (ethical, legal and social issues), genetic counseling, and practical standards and guidelines. Manuscripts reporting animal models providing clinically relevant insights into human disease mechanisms and potential therapeutics are also welcome. Manuscripts of candidate disease gene discoveries based on a small cohort size but solidified by a high standard of scientific rigor, validity and reproducibility may be considered. Rare case reports may be considered if they fill a knowledge gap in populations underrepresented in genetics research or experiencing health disparities, or inform exceptionally significant actionability in diagnosis, prognosis, and therapeutics. GIM Open promotes studies that include diverse especially under-represented populations. www.gimopen.org About Elsevier and society partnerships Elsevier has long-standing partnerships with over 600 learned societies worldwide, helping them to realize their missions and inspire and support their communities. We pride ourselves on consistently delivering outstanding publishing outcomes through strategic insight, reliable finances, global dissemination, embracing open science and open access, and championing the needs of the communities we jointly serve. www.elsevier.com/societies About American College of Medical Genetics and Genomics (ACMG) Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for nearly 2,500 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80 percent of whom are board certified in the medical genetics specialties. ACMG’s mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. www.acmg.net About the Editor-in-Chief Bo Yuan, PhD, FACMG is an Associate Professor of the Human Genome Sequencing Center (HGSC) and the Department of Molecular and Human Genetics at Baylor College of Medicine (BCM). He is also a Division Director of the Clinical Laboratories of HGSC. After receiving his Bachelor’s degree from Nankai University in China, he came to the United States and completed his PhD training in molecular and human genetics at BCM. He then received the American Board of Medical Genetics and Genomics (ABMGG) fellowship at BCM and was subsequently board-certified in Clinical Molecular Genetics and Clinical Cytogenetics. Dr. Yuan is an active laboratory geneticist and academic researcher with interest in characterizing new mechanisms of human genetic disorders, investigating, developing and implementing tools to improve molecular diagnostics and genomic data interpretation, and enhancing the visibility of genomic medicine in clinical care. He has authored and co-authored more than 60 peer-reviewed publications and book chapters. Dr. Yuan is a Fellow of the American College of Medical Genetics and Genomics (ACMG). He is also a contributing member of other professional communities, including the American Society of Human Genetics (ASHG), ClinGen Variant Curation Expert Panel, and ACMG evidence-based guideline (EBG) workgroup. He has also been a longtime reviewer for a number of journals. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Kiran Dhaliwal - Global Press & Communications Manager newsroom@elsevier.com American College of Medical Genetics and Genomics Kathy Moran - Senior Director, Communications and Public Relations kmoran@acmg.net Company Website https://www.elsevier.com/

October 27, 2022 09:00 AM Eastern Daylight Time

Image

Software Effective Solutions Subsidiary MEDCANA (OTC: SFJW) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics with Colombia Partner Firms

Software Effective Solutions Corp.

Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana is pleased to announce the successful launch of test greenhouses for microclimates and genetics with five partner firms in Colombia, South America. With significantly better economics than the US and Canada, a central location for exportation to major markets, and prime cultivation characteristics, Colombia is believed by many to have significant cultivation advantages over other regions around the world. According to Arcview Market Research, the cost to cultivate cannabis in Colombia is 60X less expensive than in Canada and 30X less than in the U.S. José Gabriel Diaz, The Company’s CEO, states, “We have begun simultaneous testing in all five partner companies. The goal is to test microclimate, genetics, local pests, and any other factors that may affect the final design and selection of genetics. The plan is to have our partners run tests with desired strands and analyze initial results.” “As well, the greenhouses are a very small fraction of the planned builds but allow us to test conditions and begin micro-testing genetics. The plan is to run one 90-day cycle and make sure the test parameters yield the expected results.” Medcana partners will also be running tests in native soil for near-term open-air cultivation possibilities for the Company. For now, the greenhouses give Medcana and partners a controlled environment to ensure native soil results are accurate. Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. The recent acquisition of a software company expanded the offering to provide traceability from plant to product. MedCana's initial focus is on developing clients and companies in Latin America, with an initial focus on Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. “In order to build something right and well, we must go slow, analyze, and test all variables. We have done a phenomenal job with the initial analysis for infrastructure, with geological, hydrological, and environmental factors. Now we want to test further. All things matter, wind currents, small changes in humidity, soil, pests, we want to make sure all is analyzed and tested,” adds Diaz. MedCana aims to build its Partner companies into one of the most advanced Cannabinoid production and processing organizations globally SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Signed. /s/ Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co Contact Details Chris Greta +1 512-587-5175 chris@chrisgreta.com Company Website https://www.medcana.net/

October 27, 2022 08:30 AM Eastern Daylight Time